CP Reports Store

Essential Benchmark Data for Dealmakers - The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2020 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

The Global Autoimmune Partnering 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the autoimmune disease partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies.

The Global Co-development Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2020 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading healthcare companies.

The Global Collaborative R&D Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2020 report provides comprehensive understanding and unprecedented access to the collaborative R&D partnering deals and agreements entered into by the worlds leading healthcare companies.

The Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2020 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies

The Global Dermatology Partnering 2014-2020 report provides comprehensive understanding and unprecedented access to the dermatology partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Central Nervous System Partnering 2014 to 2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the central nervous system (cns) partnering deals and agreements entered into by the worlds leading healthcare companies.

The Global Option and Evaluation Deals in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies.

The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2020 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.